Cyrona Cell Podcast: Stem Cell Therapy in Malaysia
Welcome to the Cyrona Cell Podcast, your trusted source for clear, doctor-led conversations about stem cell therapy and regenerative medicine in Malaysia.
Hosted by the team at Cyrona Cell in Kuala Lumpur, this podcast explores how mesenchymal stem cells (MSCs), exosome support, and evidence-informed cell-based care may help patients living with chronic inflammation, immune imbalance, and long-term degenerative conditions.
We discuss:
• How stem cell therapy works in real clinical settings
• What current research supports — and what it does not
• Eligibility and safety screening for treatment
• Conditions such as osteoarthritis, diabetes, neurological disorders, autoimmune diseases, and more
• What international patients can expect when seeking treatment in Malaysia
• Realistic outcomes, risks, and ethical standards in regenerative medicine
At Cyrona Cell, we believe in honest medicine — not hype. Every episode focuses on transparency, medical screening, patient suitability, and integrating cell therapy into a broader treatment plan.
If you are considering stem cell therapy in Kuala Lumpur and want medically grounded information before making a decision, this podcast is designed for you.
New episodes are released regularly.
Cyrona Cell Podcast: Stem Cell Therapy in Malaysia
New Wharton’s Jelly MSC Study: Why Cell Quality Testing Matters in Stem Cell Therapy
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode, we break down a new 2026 Wharton’s jelly mesenchymal stem cell (MSC) study and explain why cell potency testing may be just as important as the stem cells themselves in determining treatment success.
You’ll learn:
- What the 2026 Scientific Reports study found in patients with steroid-resistant graft-versus-host disease (GvHD)
- Why Wharton’s jelly MSCs are widely used in immune-related conditions
- How potency assays measure the real functional quality of stem cell batches
- Why were higher potency scores linked to significantly better patient outcomes
- How MSC response rates compare across multiple clinical reviews and studies
- What current research still cannot explain about long-term survival outcomes
This episode explores why consistency in cell quality may be the missing link in regenerative medicine. While Wharton’s jelly MSC therapy continues to show strong short-term response rates, the evidence suggests that not all cell batches perform the same, making potency testing a critical step in future clinical use.
Blog Link: New Wharton’s Jelly MSC Study: Why Cell Quality Testing Matters